title: Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
abstract: BACKGROUND
  The aims of this study were compare the serum visfatin and resistin levels between endometrial cancer (EC) patients and controls and evaluate their power to predict prognosis.
  
  
  METHODS
  This prospective study was conducted between March 2013 to June 2014 on the Gynecologic Oncology Department of the University of Selcuk, Konya, Turkey. A total of 42 EC patients and 42 controls were included and assessed for differences in serum visfatin and resistin levels, along with prognostic factors.
  
  
  RESULTS
  Endometrial cancer patients had significantly higher visfatin levels than control s (p: 0.011), associated with deep myometrial invasion (p: 0.019). In contrast the serum level of resistin did not significantly differ between EC patients and controls (p: 0.362). However, high resistin level in EC patients was associated with increase lymph node metastasis (p: 0.009). On logistic regression analysis, we found that serum visfatin elevation was associated with risk of myometrial invasion (OR: 1,091; 95%CI: 1.021- 1.166; p: 0.010) and serum resistin with risk of lymph node metastasis (OR: 1.018; 95%CI: 1.000- 1.035; p: 0.046). For myometrial invasion prediction, a serum visfatin level greater than 26.8 ng/mL demonstrated a sensitivity and specificity of 66.6 % and 96.4%, respectively. For lymph node metastasis prediction, the best cut-off for serum resistin level was 599ng/mL. A serum resistin level greater than this demonstrated a sensitivity and specificity of 87.5% and 77.1%, respectively.
  
  
  CONCLUSIONS
  Our data suggest that serum visfatin is elevated in patients with EC and serum visfatin and resistin levels could be used to predict the risk of advance stage lesions.
authors.affiliation: Gynecologic Oncology, Medical Faculty, University of Selcuk, Turkey E-mail : tolgaytuyan@yahoo.com.
authors.forename: Tolgay Tuyan
authors.initials: TT
authors.lastname: Ilhan
authors.forename: Aysegul
authors.initials: A
authors.lastname: Kebapcilar
authors.forename: Setenay Arzu
authors.initials: SA
authors.lastname: Yilmaz
authors.forename: Turkan
authors.initials: T
authors.lastname: Ilhan
authors.forename: Ozlem Secilmis
authors.initials: OS
authors.lastname: Kerimoglu
authors.forename: Aybuke Tazegul
authors.initials: AT
authors.lastname: Pekin
authors.forename: Fikret
authors.initials: F
authors.lastname: Akyurek
authors.forename: Ali
authors.initials: A
authors.lastname: Unlu
authors.forename: Cetin
authors.initials: C
authors.lastname: Celik
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D016889:Endometrial Neoplasms / Q000097:blood* / Q000473:pathology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009215:Myometrium / Q000378:metabolism / Q000473:pathology*; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D052243:Resistin / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D016207:Cytokines; C499624:RETN protein, human; D052243:Resistin; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human